Monday, August 10, 2009 1:59:06 PM
Meditor Pharmaceuticals...with our unique Blood Cell Morphometric Method, we will be able to provide new and effective technology to deal with early cancer detection in healthy individuals and monitor the treatment efficiency in patients diagnosed with cancer. This will revolutionize the field of oncology and may become a new standard of care in this $219.2 billion market.
...In additional news, Mr. Larry Skolnik, President of MEDITOR and Dr. Boris Farber, CEO and Chairman of AMT are continuing to develop relationships with market makers in Europe to help create additional investor awareness of Meditor and AMT on the Frankfurt and Berlin Exchanges. The company's first stop on its investor relations tour will be in Munich this Monday 16 March 2009 at Hotel Le Meridien in the Elysee II Suite.
IR Department, Meditor Pharmaceuticals (North American) Ltd., 4936 Yonge St.
Suite 727, Toronto, ON, M2N 6S3, Phone: (416) 410-3995, Fax: (416) 784-1529
and/or Dr. Boris Farber, American Medical Technologies, Inc., 1781 East 17th
Street, Suite D6, Brooklyn, NY, 11229, Phone: (347) 673-6269
http://www.reuters.com/article/pressRelease/idUS132775+12-Mar-2009+PRN20090312
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM